NCT04996511 Day Case Colectomy: Optimizing Short Stay-surgery.
| NCT ID | NCT04996511 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Joint Authority for Päijät-Häme Social and Health Care |
| Condition | Monitoring, Physiologic |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2020-01-01 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2020-01-01 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
HRV measurement of patients recovering from laparoscopic colorectal resection for any pathology.
Eligibility Criteria
Inclusion Criteria: • Colorectal resection for any pathology Exclusion Criteria: • Arrhytmias likely to cause problems with HRV measurements
Contact & Investigator
Juha KA Rinne, MD
PRINCIPAL INVESTIGATOR
Päijät Häme Central Hospital
Frequently Asked Questions
Who can join the NCT04996511 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Monitoring, Physiologic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04996511 currently recruiting?
Yes, NCT04996511 is actively recruiting participants. Contact the research team at juha.rinne@phhyky.fi for enrollment information.
Where is the NCT04996511 trial being conducted?
This trial is being conducted at Lahti, Finland.
Who is sponsoring the NCT04996511 clinical trial?
NCT04996511 is sponsored by Joint Authority for Päijät-Häme Social and Health Care. The principal investigator is Juha KA Rinne, MD at Päijät Häme Central Hospital. The trial plans to enroll 30 participants.